Urol. praxi, 2012; 13(5): 192-198

Options of radiotherapy for prostate cancer

doc.MUDr.Renata Soumarová, Ph.D., MBA, MUDr.Hana Perková, MUDr.Tomáš Blažek, Mgr.Luboš Homola, Ing.Stanislav Machala, Ing.Halina Richterová
Nemocnice Nový Jičín a Komplexní onkologické centrum Nový Jičín

Radiotherapy has been among standard cancer treatments for several decades. The last two decades have seen a very rapid technological

development that has changed our view on this modality and the current approach to prostate cancer treatment.

Randomized studies have shown that higher doses of radiation improve the clinical outcome, but also increase healthy tissue toxicity.

The introduction of conformal radiotherapy technique, intensity-modulated radiotherapy, proton therapy, stereotactic radiotherapy,

and brachytherapy has allowed dose escalation with a simultaneous reduction in toxicity.

However, there are still a number of uncertainties, particularly as to when and which technique of radiotherapy should be indicated.

The article aims to explain the most frequent questions related to radiotherapy for prostate cancer.

Keywords: external radiotherapy, brachytherapy, radiotherapy toxicity

Published: October 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Soumarová R, Perková H, Blažek T, Homola L, Machala S, Richterová H. Options of radiotherapy for prostate cancer. Urol. praxi. 2012;13(5):192-198.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Heidenreich A, Bastian PL, Bellmut J, et al. Guidelines on Prostate Cancer, EAU 2012.
    2. Merglen A, Schmidlin F, Fioretta G, et al. Short- and long-term mortality with localized prostate cancer. Arch Intern Med 2007; 167(18): 1944-1950. Go to original source... Go to PubMed...
    3. Tewari A, Divine G, Chang P, et al. Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy - a propensity scoring approach. J Urol. 2007; 177(3): 911-915. Go to original source... Go to PubMed...
    4. Kupelian PA, Elshaikh M, Reddy CA, et al. Comparison of the efficacy of local therapies for localized prostate cancer in the PSA era: a large single institution experinece with radical prostatectomy and external bean radiotherapy. J Clin Oncol 2002; 20: 3376-3385. Go to original source... Go to PubMed...
    5. Kupelian PA, Khuntia D, Potters L, et al. Radical prostatectomy, external beam radiotherapy < 72 Gy, external beam radiotherapy >= 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58: 25-33. Go to original source... Go to PubMed...
    6. Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, Pollack A. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys. 2011; 79(5): 1310-1317. Epub 2010 May 20. Go to original source... Go to PubMed...
    7. Zelefsky MJ, Fuks Z, Happersett L, et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol. 2000; 55(3): 241-249. Go to original source... Go to PubMed...
    8. Zelefsky MJ, Chan H, Hunt M, et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006; 176(4 Pt 1): 1415-1419. Go to original source... Go to PubMed...
    9. Konski A, Speier W, Hanlon A, et al. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol. 2007; 25(24): 3603-3608. Go to original source... Go to PubMed...
    10. Macbeth FR, Williams MV. Proton therapy should be tested in randomized trials. J Clin Oncol. 2008; 26(15): 2590-2591; author reply 2593-2596. Go to original source... Go to PubMed...
    11. Potters L, Morgenstern C, Calugaru E, et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2005; 173(5): 1562-1566. Go to original source... Go to PubMed...
    12. Shapiro EY, Rais-Bahrami S, Morgenstern C, et al. Long-term outcomes in younger men following permanent prostate brachytherapy. J Urol 2009; 181(4): 1665-1671; discussion 1671. Go to original source... Go to PubMed...
    13. Merrick GS, Wallner KE, Galbreath RW, et al. Biochemical and functional outcomes following brachytherapy with or without supplemental therapies in men < or = 50 years of age with clinically organ-confined prostate cancer. Am J Clin Oncol 2008; 31(6): 539-544. Go to original source... Go to PubMed...
    14. Pollack A, Zagars G, Starkshall G, et al. Conventional vs conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys 1996; 34: 555-564. Go to original source... Go to PubMed...
    15. Lawton CA, Won M, Pilepich MV, et al. Long-term treatment sequelae folllowing external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol PHys 1991; 21: 935-939. Go to original source... Go to PubMed...
    16. Dolezel M, Odrazka K, Vaculikova M, et al. Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy. Strahlenther Onkol. 2010; 186(4): 197-202. Epub 2010 Mar 26. Go to original source... Go to PubMed...
    17. Burnett AL, Aus G, Canby-Hagino ED, et al. American Urological Association Prostate Cancer Guideline Update Panel. Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol 2007; 178(2): 597-601. Go to original source... Go to PubMed...
    18. Budäus L, Bolla M, Bossi A, Cozzarini C, Crook J, Widmark A, Wiegel T. Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol. 2012; 61(1): 112-127. Epub 2011 Oct 6. Go to original source... Go to PubMed...
    19. Mitchell DM, Swindell R, Elliott T, Wylie JP, Taylor CM, Logue JP. Analysis of prostate-specific antigen bounce after I (125) permanent seed implant for localised prostate cancer. Radiother Oncol 2008; 88(1): 102-107. Go to original source... Go to PubMed...
    20. Thompson A, Keyes M, Pickles T, et al. Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounces? Int J Radiat Oncol Biol Phys 2010 Feb 2. Go to original source... Go to PubMed...
    21. Van der Kwast TH, Bolla M, Van Poppel H, Van Cangh P, Vekemans K, Da Pozzo L, Bosset JF, Kurth KH, Schröder FH, Collette L; EORTC 22911. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol. 2007 Sep 20; 25(27): 4178-4186. Go to original source... Go to PubMed...
    22. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Souchon R, Stöckle M, Rübe C, Weissbach L, Althaus P, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W, Miller K. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
    23. Stephenson AJ, Bolla M, Briganti A, Cozzarini C, Moul JW, Roach III M, van Poppel H, Zietman A. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. J Clin Oncol. 2009 Jun 20;27 (18): 2924-2930. Epub 2009 May 11. Eur Urol. 2012; 61(3): 443-451. Epub 2011 Oct 21.
    24. Loeb S, Roehl KA, Viprakasit DP, Catalona WJ. Long-term rates of undetectable PSA with initial observation and delayed salvage radiotherapy after radical prostatectomy. Eur Urol. 2008; 54(1): 88-94. Epub 2008 Apr 1. Go to original source... Go to PubMed...
    25. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Billiet I, Torecilla JL, Pfeffer R, Cutajar CL, Van der Kwast T, Collette L. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010 Nov; 11(11): 1066-1073. Epub 2010 Oct 7. Go to original source... Go to PubMed...
    26. Lawton CA, DeSilvio M, Roach M 3rd, Uhl V, Kirsch R, Seider M, Rotman M, Jones C, Asbell S, Valicenti R, Hahn S, Thomas CR Jr. An update of the phase III trial comparing whole  pelvic  to  prostate  only  radiotherapy  and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. 2007; 69(3): 646-655. Epub 2007 May 24. Go to original source...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.